Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3001 - A novel multimodal treatment strategy for cancer cachexia; rationale and motivation for the MENAC (Multimodal – Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial


10 Sep 2017


Poster display session


End-of-life Care


Stein Kaasa


Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388


S. Kaasa1, B. Laird2, T. Balstad3, G. Stene4, V. Baracos5, A. Bye6, F. Strasser7, M. Fallon8, K. Fearon9

Author affiliations

  • 1 Department Of Cancer Treatment, Oslo University Hospital, 0424 - Oslo/NO
  • 2 Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh/GB
  • 3 European Palliative Care Research Centre (prc), Department Of Cancer Research And Molecular Medicine, Faculty Of Medicine, Norwegian University of Science and Technology, Trondheim/NO
  • 4 Department Of Neuroscience, Faculty Of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim/NO
  • 5 Department Of Oncology, Division Of Palliative Care Medicine, Department of Oncology, Division of Palliative Care Medicine, Alberta/CA
  • 6 Oslo University Hospital/ Oslo And Akershus University College Of Applied Sciences, Regional Advisory Unit for Palliative Care, Department of Oncology/ Dept of Nursing and Health Promotion, Oslo/NO
  • 7 Department Internal Medicine & Centre For Palliative Care, Kantonsspital St. Gallen, 9007 - St. Gallen/CH
  • 8 Edinburgh Cancer Research Centre, University of Edinburgh, EH4 2XR - Edinburgh/GB
  • 9 Department Of Surgery,, Royal Infirmary, Edinburgh/GB


Abstract 3001


Cancer cachexia is a multifactorial syndrome characterized by an on-going loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support alone. Cachexia has a high prevalence in cancer and a major impact on patient physical function, morbidity and mortality. Despite the consequences of cachexia, there is no licensed treatment and no standard of care. It has been argued that the multifactorial genesis of cachexia lends itself well to therapeutic targeting through a multimodal treatment. Following a successful phase II trial, a phase III trial is underway.

Trial design

MENAC is a multicentre, open, randomized phase III study comparing multimodal intervention and standard cancer care versus standard cancer care alone. Patients treated for incurable lung and pancreatic cancer will be allocated randomly to receive the multimodal intervention, either immediately, or after endpoint at six weeks. The intervention is based on evidence to date and consists of Non-steroidal Anti-inflammatory Drugs (NSAID) and an EPA containing oral nutrition supplement to reduce inflammation, a physical exercise progamme consisting of both resistance and aerobic exercises to increase anabolism, as well as dietary counselling aiming to promote energy and protein balance. The overall aim is to reduce weight loss, improve food intake and maintain physical function by establish basic supportive care for cachexia. From a patient perspective, a short-term effect will be to improve physical and psychological function and reduce symptom burden. Change in body weight is primary endpoint. Secondary endpoints are change in muscle mass (CT technique) and physical activity (ActivPAL activity meter). There are several exploratory endpoints. The trial is ongoing and patients are recruited from several sites in Europa and Canada, we aim for 240 patients. If positive, the results will be practice changing for supportive treatment of patients with cancer.

Clinical trial identification


Legal entity responsible for the study

NTNU through PRC is coordinating the running of the trial.


The European Union through the European Clinical Research Infrastructures Network (ECRIN) Canadian Institute for Health Research Marie Curie and Raising Tide foundation Norwegian Cancer union The Omega 3 capsules are recieved free of charge from Pronova BioPharma Norge AS. The oral nutritional supplements are received free of charge from Abbott Nutrition


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.